Allogene Therapeutics ALLO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $131.96M-30.6% | $150.15M-21.9% | $166.49M-17.6% | $180.04M-11.4% | $190.24M-11.5% | ||
| $55.88M-11.2% | $56.78M-12.9% | $58.53M-12.5% | $61.12M-9.6% | $62.93M-10.2% | ||
| $190.22M-29.3% | $209.32M-23.4% | $227.4M-23.7% | $254.27M-12.0% | $268.89M-9.8% | ||
| -$190.22M+29.3% | -$209.32M+23.4% | -$227.4M+23.6% | -$254.27M+12.0% | -$268.89M+9.8% | ||
| $1.23M+270% | $1.08M+494% | $843K+743% | $599K— | $331K-91.2% | ||
| $16.46M-3.2% | $18.43M+14.8% | $15.83M— | $17.81M— | $17.01M— | ||
| -$173.76M+31.1% | -$190.89M+25.9% | -$212.02M+25.2% | -$236.91M+15.2% | -$252.32M+13.7% | ||
| -$0.77+37.4% | -$0.87+34.6% | -$0.98+37.2% | -$1.11+31.1% | -$1.23+31.7% | ||
| -$178.09M+30.4% | -$196.96M+24.1% | -$214.87M+24.3% | -$241.63M+12.1% | -$255.7M+9.9% | ||
| -$190.22M+29.3% | -$209.32M+23.4% | -$227.4M+23.6% | -$254.27M+12.0% | -$268.89M+9.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Allogene Therapeutics profitable?
- Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.
- What is Allogene Therapeutics's earnings per share?
- Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.
- Where does Allogene Therapeutics's income statement data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.